Latest Naproxcinod Stories
An updated study published in this week's PLoS Medicine gives some new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that among these commonly used drugs, naproxen and low dose ibuprofen are least likely to increase cardiovascular risk whereas diclofenac, even in doses available without prescription, elevates risk.
ROCHESTER, N.Y. and SOPHIA ANTIPOLIS, France, March 3 /PRNewswire/ -- NicOx S.A.
LA JOLLA, Calif., July 8 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.
MORRISTOWN, N.J., March 18 /PRNewswire/ -- Concerns still persist within the general clinical community regarding the cardiovascular and gastrointestinal risk that is associated with the use of analgesics such as the nonsteroidal anti-inflammatory drugs (NSAIDs).
SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A.
SOPHIA ANTIPOLIS, France, December 23 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced the results of a phase 2a study for TPI 1020, conducted in 62 patients with Chronic Obstructive Pulmonary Disease (COPD) by its partner Topigen Pharmaceuticals Inc.
SOPHIA ANTIPOLIS, France, December 19 /PRNewswire-FirstCall/ -- NicOx S.A.
SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod.
SOPHIA ANTIPOLIS, France, December 2 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient).